This approach identified for the first time 3 novel lead compounds that competitively inhibit Stat3 binding to its pY-peptide ligand, that are selective for Stat3 vs. Stat1 and that also induce apoptosis preferentially of breast cancer cells lines with constitutively activated Stat3. This evidence concerns the gene STAT1 and breast cancer.